Application 761371
- Type
- BLA
- Sponsor
- GENENTECH INC
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761371 | Ocrevus Zunovo | ocrelizumab and hyaluronidase-ocsq | 351(a) | Rx | 2026-09-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | OCREVUS ZUNOVO | OCRELIZUMAB AND HYALURONIDASE-OCSQ | INJECTABLE;INJECTION | 40MG;1000UNITS PER ML | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ocrevus Zunovo | OCRELIZUMAB AND HYALURONIDASE | Genentech, Inc. | b216af61-99d0-42a3-afc2-b5bf86df1ec0 | 2026-08-17 | Warnings, Adverse reactions | BLA761371 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.